NO20085259L - Framgangsmate - Google Patents

Framgangsmate

Info

Publication number
NO20085259L
NO20085259L NO20085259A NO20085259A NO20085259L NO 20085259 L NO20085259 L NO 20085259L NO 20085259 A NO20085259 A NO 20085259A NO 20085259 A NO20085259 A NO 20085259A NO 20085259 L NO20085259 L NO 20085259L
Authority
NO
Norway
Prior art keywords
cell
sirna molecule
carrier
photosensitizer
kits
Prior art date
Application number
NO20085259A
Other languages
English (en)
Other versions
NO342202B1 (no
Inventor
Sigurd Boe
Eivind Johannes Hovig
Original Assignee
Pci Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pci Biotech As filed Critical Pci Biotech As
Publication of NO20085259L publication Critical patent/NO20085259L/no
Publication of NO342202B1 publication Critical patent/NO342202B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SAMMENDRAG Foreliggende oppfinnelse vedrører en fremgangsmåte for innføring av et siRNA-molekyl inn i cytosolen til en celle, idet framgangsmåten omfatter i) å bringe cellen i kontakt med et siRNA-mo lekyl, en bærer og et fotosensibiliseringsmiddel, og ii) å bestråle cellen med lys av en bølgelengde som er effektiv til å aktivere fotosensibiliseringsmidlet, hvori bæreren omfatter et kationisk polyamin slik som et lipopolyamin i en ikke- liposomal formulering, et polyetylenimin (PEI", en betasyklodekstrinaminpolymer, en dendrimer som inneholder en aminogruppe, eller et kationisk peptid. Celler eller populasjoner av celler som kan framskaffes ved framgangsmåten, preparat som inneholder et siRNA- molekyl og bærermolekylet, sett (kits) og terapeutiske anvendelser av ovennevnte stilles også til rådighet.
NO20085259A 2006-07-11 2008-12-16 Framgangsmåte for innføring av siRNA i celler ved fotokjemisk internalisering NO342202B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0613753.3A GB0613753D0 (en) 2006-07-11 2006-07-11 Method
PCT/GB2007/002569 WO2008007073A2 (en) 2006-07-11 2007-07-11 Method for introducing sirna into cells by photochemical internalisation

Publications (2)

Publication Number Publication Date
NO20085259L true NO20085259L (no) 2009-02-10
NO342202B1 NO342202B1 (no) 2018-04-16

Family

ID=36955439

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085259A NO342202B1 (no) 2006-07-11 2008-12-16 Framgangsmåte for innføring av siRNA i celler ved fotokjemisk internalisering

Country Status (15)

Country Link
US (2) US20090297487A1 (no)
EP (1) EP2037962B1 (no)
JP (1) JP5269783B2 (no)
CN (1) CN101573140B (no)
AU (1) AU2007274056B2 (no)
CA (1) CA2657999C (no)
DK (1) DK2037962T3 (no)
ES (1) ES2525222T3 (no)
GB (1) GB0613753D0 (no)
NO (1) NO342202B1 (no)
NZ (1) NZ573775A (no)
PL (1) PL2037962T3 (no)
RU (1) RU2510826C2 (no)
WO (1) WO2008007073A2 (no)
ZA (1) ZA200810684B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
CN101952434B (zh) * 2007-12-13 2016-11-16 聚加转染公司 使用合成的聚合物递送对基因沉默有活性的核酸的工具
WO2009109862A2 (en) * 2008-03-06 2009-09-11 Rolf Lewensohn Improved cancer therapeutics
WO2010017328A2 (en) * 2008-08-06 2010-02-11 Rgo Biosciences Llc Cyclodextrin conjugates
EP2542678B1 (en) 2010-03-04 2017-04-12 InteRNA Technologies B.V. A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT
CN101831046B (zh) * 2010-03-30 2012-10-31 上海交通大学 交联剂和聚氨酯硬质泡沫材料及其制备方法
EP2591106A1 (en) 2010-07-06 2013-05-15 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
EP3369818B1 (en) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna for treating head and neck cancer
EP2804633A4 (en) * 2012-01-18 2015-10-14 Univ Utah Res Found ARGININE-PREPARED BIODEGRADABLE POLYMERS WITH HIGH MOLECULAR WEIGHT
CN112370532B (zh) * 2012-10-08 2024-11-01 生物技术传送科技有限责任公司 作为转染试剂的羧化多胺衍生物
EP2917348A1 (en) 2012-11-06 2015-09-16 InteRNA Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
AU2014287044B2 (en) * 2013-07-12 2020-02-06 Genentech, Inc. Elucidation of ion exchange chromatography input optimization
AU2014314149B2 (en) * 2013-08-28 2019-12-19 Pci Biotech As Compound and method for vaccination and immunisation
EP3034539A1 (en) * 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
CN104878044B (zh) * 2015-04-29 2018-07-17 常州百代生物科技有限公司 一种脂类化合物siRNA转染试剂
EP3452091A1 (en) * 2016-05-05 2019-03-13 CosmoPHOS Ltd Nano-systems for therapy and/or diagnosis and/or therapy monitoring and/or theranostics of disease
CN106924746B (zh) * 2017-03-03 2020-11-03 中山大学 复合基因载体及其应用
CN107011511B (zh) * 2017-06-01 2019-04-26 西南大学 一种原卟啉荧光碳点及制备方法和应用
EP3808849A1 (en) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
CN111566212A (zh) 2017-11-03 2020-08-21 因特尔纳技术有限公司 miRNA分子，等同物，安塔够妙或其来源用于治疗和/或诊断与神经元缺陷相关的病症和/或疾病或用于神经元生成和/或再生
GB201801169D0 (en) 2018-01-24 2018-03-07 Pci Biotech As Method
WO2019222329A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
WO2019241486A1 (en) 2018-06-13 2019-12-19 Voyager Therapeutics, Inc. Engineered 5' untranslated regions (5' utr) for aav production
CN112770812A (zh) 2018-07-24 2021-05-07 沃雅戈治疗公司 产生基因治疗制剂的系统和方法
WO2020072849A1 (en) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
WO2020072844A1 (en) 2018-10-05 2020-04-09 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding aav production proteins
US20210371470A1 (en) 2018-10-12 2021-12-02 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
CN113166781A (zh) 2018-10-15 2021-07-23 沃雅戈治疗公司 在杆状病毒/Sf9系统中大规模生产rAAV的表达载体
SG11202107645RA (en) 2019-01-18 2021-08-30 Voyager Therapeutics Inc Methods and systems for producing aav particles
WO2020171889A1 (en) 2019-02-19 2020-08-27 University Of Rochester Blocking lipid accumulation or inflammation in thyroid eye disease
EP3962536A1 (en) 2019-04-29 2022-03-09 Voyager Therapeutics, Inc. Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
EP4010465A1 (en) 2019-08-09 2022-06-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP4022070A1 (en) 2019-08-26 2022-07-06 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
WO2022032153A1 (en) 2020-08-06 2022-02-10 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
GB202101726D0 (en) 2021-02-08 2021-03-24 Pci Biotech As Method
WO2022187473A2 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN114452406B (zh) * 2022-03-16 2023-05-23 安徽工程大学 一种抑菌材料及其制备方法和应用
US20260085328A1 (en) 2022-09-08 2026-03-26 Voyager Therapeutics, Inc. Controlled expression of viral proteins
KR20250129743A (ko) 2022-12-29 2025-08-29 보이저 테라퓨틱스, 인크. Mapt를 조절하기 위한 조성물 및 방법
CN118207158B (zh) * 2023-06-21 2024-08-27 天津医科大学眼科医院 一种细胞内来源的纳米囊泡的制备方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
RU2066552C1 (ru) 1996-02-12 1996-09-20 Товарищество с ограниченной ответственностью "Био Прогресс" Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней
FR2763943B1 (fr) * 1997-05-28 1999-07-09 Rhone Poulenc Rorer Sa Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
EP1339862B1 (en) 2000-11-29 2014-01-08 PCI Biotech AS Photochemical internalization for virus-mediated molecule delivery into the cytosol
PT1346059E (pt) * 2000-11-29 2012-06-01 Pci Biotech As Internalização fotoquímica para distribuição de moléculas no citosol
CA2429814C (en) * 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
US20050008617A1 (en) * 2002-09-28 2005-01-13 Massachusetts Institute Of Technology Compositions and methods for delivery of short interfering RNA and short hairpin RNA
EP1585756B1 (en) * 2002-11-26 2010-04-21 University of Massachusetts Delivery of sirnas
FR2858628B1 (fr) 2003-08-04 2008-01-04 Polyplus Transfection Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines
GB0415263D0 (en) * 2004-07-07 2004-08-11 Norwegian Radium Hospital Res Method
US20060051405A1 (en) 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method

Also Published As

Publication number Publication date
EP2037962B1 (en) 2014-09-03
WO2008007073A3 (en) 2008-04-10
JP2010504080A (ja) 2010-02-12
RU2510826C2 (ru) 2014-04-10
ES2525222T3 (es) 2014-12-19
CA2657999C (en) 2015-02-24
CN101573140B (zh) 2014-04-23
CN101573140A (zh) 2009-11-04
US20120264807A1 (en) 2012-10-18
NO342202B1 (no) 2018-04-16
DK2037962T3 (en) 2014-12-15
EP2037962A2 (en) 2009-03-25
JP5269783B2 (ja) 2013-08-21
US9700622B2 (en) 2017-07-11
GB0613753D0 (en) 2006-08-23
AU2007274056A1 (en) 2008-01-17
US20090297487A1 (en) 2009-12-03
PL2037962T3 (pl) 2015-03-31
ZA200810684B (en) 2010-08-25
NZ573775A (en) 2012-11-30
WO2008007073A2 (en) 2008-01-17
AU2007274056B2 (en) 2013-08-01
RU2008150847A (ru) 2010-06-27
CA2657999A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
NO20085259L (no) Framgangsmate
Varkouhi et al. Endosomal escape pathways for delivery of biologicals
Chen et al. Nature-inspired creation of protein− polysaccharide conjugate and its subsequent assembly onto a patterned surface
BR112013030432A2 (pt) método para preparar um peptídeo conjugado alvo para uma enzima lisossomal recombinante, método para preparar uma molécula para terapia de reposição de enzima, conjugado, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um paciente sofrendo da doença de pompe, doença de fabry, e doença de gaucher, mps i, mps ii, mps vii, tay sachs, sandhoff, alfa-manosidose, e wohlman, sequência de dna e sequência de aminoácidos
Abul‐Haija et al. Biocatalytically Triggered Co‐Assembly of Two‐Component Core/Shell Nanofibers
CY1118437T1 (el) Στοχευομενη απελευθερωση φαρμακων θεραπευτικων νουκλεϊνικων οξεων και λειτουργικων νουκλεϊνικων οξεων σε κυτταρα θηλαστικου μεσω ανεπαφων θανατωμενων βακτηριακων κυτταρων
Lim et al. Polydopamine adhesion: catechol, amine, dihydroxyindole, and aggregation dynamics
Scholz et al. Correlation of length of linear oligo (ethanamino) amides with gene transfer and cytotoxicity
Choi et al. Multifunctional siRNA delivery system: Polyelectrolyte complex micelles of six‐arm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide
WO2008079973A9 (en) Egfr binding peptides and uses thereof
WO2006060182A3 (en) HIGHLY BRANCHED HK PEPTIDES AS EFFECTIVE CARRIERS OF siRNA
Goyal et al. Linear PEI nanoparticles: efficient pDNA/siRNA carriers in vitro and in vivo
PE20091388A1 (es) Moleculas y metodos para modular el componente de complemento
EP3338790A3 (en) Oligopeptidic compounds and uses thereof
WO2009083225A3 (en) Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
Tu et al. Computational Investigations of a Peptide‐Modified Dendrimer Interacting with Lipid Membranes
Nakamura et al. DNA‐modified artificial viral capsids self‐assembled from DNA‐conjugated β‐annulus peptide
WO2007097903A3 (en) Hiv fusion inhibitor peptides with improved biological properties
WO2022026906A3 (en) Lysosomal targeting molecules comprising knottin peptides and related compositions and methods
BRPI0410562A (pt) molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo
Holley et al. Endolytic, pH-responsive HPMA-b-(l-Glu) copolymers synthesized via sequential aqueous RAFT and ring-opening polymerizations
Lv et al. Synergistic Eradication of Bacterial Biofilms via Phage‐Driven EPS Disruption and Click‐Activated AIE Photosensitization
Che et al. Comparison of biological responses of polymers based on imine and disulfide backbones for siRNA delivery
Kye et al. Synthesis and purification of self‐assembling peptide‐oligonucleotide conjugates by solid‐phase peptide fragment condensation
CN101475643B (zh) 一种双单链抗体强化融合蛋白dFv-LDP-AE及其制备方法和应用

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees